A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
Phase 2
Not yet recruiting
- Conditions
- NPCHNSCCRecurrenceMetastasis
- Interventions
- Biological: IAE0972+DocetaxelBiological: IAE0972+GemcitabineBiological: IAE0972+TaxanesBiological: IAE0972+Capecitabine
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06719479
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
Phase 1
Recruiting
- Conditions
- Advanced Malignant NeoplasmAdvanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT06581419
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06504732
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06292208
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer
Phase 1
Not yet recruiting
- Conditions
- Bladder Cancer
- Interventions
- Combination Product: IAP0971＋BCG
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 236
- Registration Number
- NCT06255964
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06223841
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT05991583
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors
Phase 1
Recruiting
- Conditions
- HER2 Gene Mutation
- Interventions
- Combination Product: Injection of IAH0968+Gemcitabine+CisplatinCombination Product: Gemcitabine+Cisplatin
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 136
- Registration Number
- NCT05991518
- Locations
- 🇨🇳
Fudan University Affiliated Zhongshan Hospital, Shanghai, China
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- HER2 Gene Mutation
- Interventions
- Combination Product: Injection of IAH0968 + CAPEOXCombination Product: PLACEBO+CAPEOX
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 279
- Registration Number
- NCT05673512
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05396339
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
🇨🇳Affilated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
© Copyright 2025. All Rights Reserved by MedPath